Characterization the prognosis role and effects of snoRNAs in melanoma patients
Lei-Yun Wang
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorJia-Nan Song
Oujiang Laboratory, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorYi-Xuan Chen
Oujiang Laboratory, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorYing Zhu
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorHui-Li Ren
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorCorresponding Author
Qiu-Qi Li
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, China
Correspondence
Shao-Hui Zhang, Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China.
Email: [email protected]
Qiu-Qi Li, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, Hubei Province 430000, China.
Emal:
Email: [email protected]
Search for more papers by this authorCorresponding Author
Shao-Hui Zhang
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Correspondence
Shao-Hui Zhang, Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China.
Email: [email protected]
Qiu-Qi Li, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, Hubei Province 430000, China.
Emal:
Email: [email protected]
Search for more papers by this authorLei-Yun Wang
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorJia-Nan Song
Oujiang Laboratory, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorYi-Xuan Chen
Oujiang Laboratory, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, China
Search for more papers by this authorYing Zhu
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorHui-Li Ren
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Search for more papers by this authorCorresponding Author
Qiu-Qi Li
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, China
Correspondence
Shao-Hui Zhang, Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China.
Email: [email protected]
Qiu-Qi Li, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, Hubei Province 430000, China.
Emal:
Email: [email protected]
Search for more papers by this authorCorresponding Author
Shao-Hui Zhang
Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Department of Pharmacy, Wuhan No.1 Hospital, Wuhan, China
Correspondence
Shao-Hui Zhang, Department of Pharmacy, Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China.
Email: [email protected]
Qiu-Qi Li, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science & Technology (HUST), Wuhan, Hubei Province 430000, China.
Emal:
Email: [email protected]
Search for more papers by this authorLei-Yun Wang, Jia-Nan Song and Yi-Xuan Chen contributed equally to this work and share first authorship.
Abstract
Melanoma is a melanocyte-derived malignant cancer and is known for its early metastasis and high mortality rates. It is a highly cutaneous tumour disease that could be related to the abnormal immune microenvironment, and the identification of reliable diagnostic and prognostic markers is crucial for improving patient outcomes. In the search for biomarkers, various types of RNAs have been discovered and recognized as reliable prognostic markers. Among these, small nucleolar RNAs (snoRNAs) have emerged as a promising avenue for studying early diagnosis and prognostic markers in tumours due to their widespread presence in tissues, tumour specificity and stability. In our study, we analysed snoRNAs data from melanoma samples in the TCGA-SKCM cohort and developed a prognostic model comprising 12 snoRNAs (SNORD9, SNORA31, SNORD14E, SNORA14A, SNORA5A, SNORD83A, SNORA75, AL096855, AC007684, SNORD14A, SNORA65 and AC004839). This model exhibited unique prognostic accuracy and demonstrated a significant correlation with the immune infiltration tumour microenvironment. Additionally, analysis of the GSE213145 dataset, which explored the sensitivity and resistance of immune checkpoint inhibitors, further supported the potential of snoRNAs as prognostic markers for immunotherapy. Overall, our study contributes reliable prognostic and immune-related biomarkers for melanoma patients. These findings can offer valuable insights for the future discovery of novel melanoma treatment strategies and hold promise for improving clinical outcomes in melanoma patients.
CONFLICT OF INTEREST STATEMENT
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Open Research
DATA AVAILABILITY STATEMENT
The datasets analysed for this study can be found in the TCGA-SKCM project (https://portal.gdc.cancer.gov/) and the GEO database (https://www.ncbi.nlm.nih.gov/geo/).
Supporting Information
| Filename | Description |
|---|---|
| exd14944-sup-0001-AppendixS1.docxWord 2007 document , 1.2 MB |
Appendix S1. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Yde SS, Sjoegren P, Heje M, Stolle LB. Mucosal Melanoma: a Literature Review. Curr Oncol Rep. 2018; 20(3): 28. doi:10.1007/s11912-018-0675-0
- 2Mohammadpour A, Derakhshan M, Darabi H, Hedayat P, Momeni M. Melanoma: where we are and where we go. J Cell Physiol. 2019; 234(4): 3307-3320. doi:10.1002/jcp.27286
- 3Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1): 17-48. doi:10.3322/caac.21763
- 4Xiao H, Feng X, Liu M, Gong H, Zhou X. SnoRNA and lncSNHG: advances of nucleolar small RNA host gene transcripts in anti-tumor immunity. Front Immunol. 2023; 14:1143980. doi:10.3389/fimmu.2023.1143980
- 5Williams GT, Farzaneh F. Are snoRNAs and snoRNA host genes new players in cancer? Nat Rev Cancer. 2012; 12(2): 84-88. doi:10.1038/nrc3195
- 6Huang ZH, Du YP, Wen JT, Lu BF, Zhao Y. snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. Cell Death Dis. 2022; 8(1): 259. doi:10.1038/s41420-022-01056-8
- 7Falaleeva M, Pages A, Matuszek Z, et al. Dual function of C/D box small nucleolar RNAs in rRNA modification and alternative pre-mRNA splicing. Proc Natl Acad Sci U S A. 2016; 113(12): E1625-E1634. doi:10.1073/pnas.1519292113
- 8Liang J, Wen J, Huang Z, Chen XP, Zhang BX, Chu L. Small nucleolar RNAs: insight into their function in cancer. Front Oncol. 2019; 9: 587. doi:10.3389/fonc.2019.00587
- 9Wajahat M, Bracken CP, Orang A. Emerging functions for snoRNAs and snoRNA-derived fragments. Int J Mol Sci. 2021; 22(19):10193. doi:10.3390/ijms221910193
- 10Stepanov GA, Filippova JA, Komissarov AB, Kuligina EV, Richter VA, Semenov DV. Regulatory role of small nucleolar RNAs in human diseases. Biomed Res Int. 2015; 2015:206849. doi:10.1155/2015/206849
- 11Cui C, Liu Y, Gerloff D, et al. NOP10 predicts lung cancer prognosis and its associated small nucleolar RNAs drive proliferation and migration. Oncogene. 2021; 40(5): 909-921. doi:10.1038/s41388-020-01570-y
- 12Liu Y, Zhao C, Wang G, et al. SNORD1C maintains stemness and 5-FU resistance by activation of Wnt signaling pathway in colorectal cancer. Cell Death Dis. 2022; 8(1): 200. doi:10.1038/s41420-022-00996-5
- 13Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas Pan-cancer analysis project. Nat Genet. 2013; 45(10): 1113-1120. doi:10.1038/ng.2764
- 14Hossain SM, Gimenez G, Stockwell PA, et al. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures. Front Immunol. 2022; 13:955063. doi:10.3389/fimmu.2022.955063
- 15Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12(5): 453-457. doi:10.1038/nmeth.3337
- 16Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 2021; 12:680407. doi:10.3389/fimmu.2021.680407
- 17Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch Pathol Lab Med. 2001; 125(10): 1295-1306. doi:10.5858/2001-125-1295-mm
- 18Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014; 28(6): 1005-1011.
- 19Rashid S, Shaughnessy M, Tsao H. Melanoma classification and management in the era of molecular medicine. Dermatol Clin. 2023; 41(1): 49-63. doi:10.1016/j.det.2022.07.017
- 20Lin WM, Fisher DE. Signaling and immune regulation in melanoma development and responses to therapy. Annu Rev Pathol. 2017; 12: 75-102. doi:10.1146/annurev-pathol-052016-100208
- 21Pitcovski J, Shahar E, Aizenshtein E, Gorodetsky R. Melanoma antigens and related immunological markers. Crit Rev Oncol Hematol. 2017; 115: 36-49. doi:10.1016/j.critrevonc.2017.05.001
- 22Sklavenitis-Pistofidis R, Getz G, Ghobrial I. Single-cell RNA sequencing: one step closer to the clinic. Nat Med. 2021; 27(3): 375-376. doi:10.1038/s41591-021-01276-y
- 23Wang Z, Gerstein M, Snyder M. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009; 10(1): 57-63. doi:10.1038/nrg2484
- 24Mei J, Tian H, Huang HS, et al. Cellular models of development of ovarian high-grade serous carcinoma: a review of cell of origin and mechanisms of carcinogenesis. Cell Prolif. 2021; 54(5):e13029. doi:10.1111/cpr.13029
- 25Li Y, Zheng Q, Bao C, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 2015; 25(8): 981-984. doi:10.1038/cr.2015.82
- 26Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016; 96(4): 1297-1325. doi:10.1152/physrev.00041.2015
- 27Van der Werf J, Chin CV, Fleming NI. SnoRNA in cancer progression, metastasis and immunotherapy response. Biology. 2021; 10(8):80. doi:10.3390/biology10080809
- 28Cai C, Peng Y, Shen E, et al. Identification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model. EBioMedicine. 2022; 76:103866. doi:10.1016/j.ebiom.2022.103866
- 29Zhuo Y, Li S, Hu W, et al. Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway. J Immunother Cancer. 2022; 10(5): e004113. doi:10.1136/jitc-2021-004113
- 30Dsouza VL, Adiga D, Sriharikrishnaa S, Suresh PS, Chatterjee A, Kabekkodu SP. Small nucleolar RNA and its potential role in breast cancer - a comprehensive review. Biochim Biophys Acta Rev Cancer. 2021; 1875(1):188501. doi:10.1016/j.bbcan.2020.188501
- 31Davanian H, Balasiddaiah A, Heymann R, et al. Ameloblastoma RNA profiling uncovers a distinct non-coding RNA signature. Oncotarget. 2017; 8(3): 4530-4542. doi:10.18632/oncotarget.13889
- 32Wang K, Song X, Li X, Zhang Z, Xie L. Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancer. Future Oncol. 2022; 18(7): 821-832. doi:10.2217/fon-2021-1278
- 33Michael JV, Wurtzel JGT, Mao GF, et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth. Blood. 2017; 130(5): 567-580. doi:10.1182/blood-2016-11-751099
- 34Zhu J, Mao S, Zhen N, et al. SNORA14A inhibits hepatoblastoma cell proliferation by regulating SDHB-mediated succinate metabolism. Cell Death Dis. 2023; 9(1): 36. doi:10.1038/s41420-023-01325-0
- 35Yang K, Oak ASW, Slominski RM, Brożyna AA, Slominski AT. Current molecular markers of melanoma and treatment targets. Int J Mol Sci. 2020; 21(10):3535. doi:10.3390/ijms21103535
- 36Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L. Molecular markers and targets in melanoma. Cell. 2021; 10(9): 2320. doi:10.3390/cells10092320
- 37Liu D, Yang X, Wu X. Tumor immune microenvironment characterization identifies prognosis and immunotherapy-related gene signatures in melanoma. Front Immunol. 2021; 12:663495. doi:10.3389/fimmu.2021.663495
- 38Lafaille FG, Harschnitz O, Lee YS, et al. Human SNORA31 variations impair cortical neuron-intrinsic immunity to HSV-1 and underlie herpes simplex encephalitis. Nat Med. 2019; 25(12): 1873-1884. doi:10.1038/s41591-019-0672-3
- 39Moundir A, Ouair H, Benhsaien I, et al. Genetic diagnosis of inborn errors of immunity in an emerging country: a retrospective study of 216 Moroccan patients. J Clin Immunol. 2023; 43(2): 485-494. doi:10.1007/s10875-022-01398-z
- 40Huang L, Liang XZ, Deng Y, et al. Prognostic value of small nucleolar RNAs (snoRNAs) for colon adenocarcinoma based on RNA sequencing data. Pathol Res Pract. 2020; 216(6):152937. doi:10.1016/j.prp.2020.152937
- 41Zhang L, Xin M, Wang P. Identification of a novel snoRNA expression signature associated with overall survival in patients with lung adenocarcinoma: a comprehensive analysis based on RNA sequencing dataset. Math Biosci Eng. 2021; 18(6): 7837-7860. doi:10.3934/mbe.2021389
Citing Literature
